ImmunityBio Achieves 700% Revenue Growth, Expands Anktiva® Lung Cancer Approvals Globally
ImmunityBio, Inc. recently reported impressive financial growth and significant regulatory advancements for its immunotherapy product, ANKTIVA. The company’s net product revenue for ANKTIVA reached approximately $113 million in 2025, showcasing a remarkable 700% increase year-over-year. This growth is reflected in a report released on February 23, 2026.
Record Revenue Growth and Unit Sales
In 2025, ANKTIVA also saw a quarter-over-quarter revenue growth of 20% and a staggering 750% increase in unit sales volume compared to 2024. This sustained momentum positions ANKTIVA for continued commercial success in the future.
Global Regulatory Approvals
- ANIKTIVA secured authorization in four key jurisdictions: the United States, the United Kingdom, the European Union, and Saudi Arabia.
- Approval for use in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) was granted across these regions, impacting a total of 33 countries.
- Most notably, the Saudi Food and Drug Authority (SFDA) granted the first global approval for ANKTIVA’s use in combination with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC) in January 2026.
Strategic Partnerships
To further enhance market penetration, ImmunityBio formed a distribution partnership with Accord Healthcare in the EU, leveraging a robust sales force across 30 countries. Additionally, collaborations with local partners in Saudi Arabia aim to expand access to ANKTIVA throughout the Middle East and North Africa (MENA) region.
Clinical Development and Pipeline Expansion
ImmunityBio is advancing a comprehensive global strategy to establish ANKTIVA as a foundational treatment option within its Cancer BioShield platform. This platform aims to stimulate the immune system’s response against various cancers through ongoing and planned clinical trials targeting multiple tumor types.
Long-Term Patent Protection
ImmunityBio holds multiple patents protecting ANKTIVA’s combinations, including those with checkpoint inhibitors, ensuring exclusive rights until beyond 2035. This strategic advantage supports the company’s commitment to ongoing innovation.
Key Financial Highlights
| Metric | 2025 | 2024 |
|---|---|---|
| Net Product Revenue | $113 million | $14.4 million |
| Year-over-Year Growth | 700% | N/A |
| Unit Sales Volume Increase | 750% | N/A |
Looking Ahead
The company plans to pursue accelerated regulatory pathways for ANKTIVA in additional jurisdictions while expanding its therapeutic indications. With the anticipated commercial launch in Saudi Arabia and discussions with U.S. regulators, ImmunityBio is poised for future growth.
